Research Article
Changes in Anterior Chamber Parameters Measured by Pentacam in Coronavirus Disease 2019 Infection: A Longitudinal Study

Saeed Shokoohi-Rad, Mojtaba Abrishami, Elham Bakhtiari, Asma Payandeh, and Hamid-Reza Heidarzadeh

Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Hamid-Reza Heidarzadeh; dr.hamidreza.heidarzade@gmail.com

Received 7 September 2021; Revised 16 December 2021; Accepted 17 January 2022; Published 1 February 2022

Academic Editor: Alessandro Meduri

Copyright © 2022 Saeed Shokoohi-Rad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To evaluate changes in anterior segment parameters measured by imaging in coronavirus disease 2019 (COVID-19) infection.

Methods. This longitudinal observational study included patients who recovered from COVID-19. All subjects exhibited a confirmed diagnosis of COVID-19 with a positive result of nasopharyngeal reverse transcription-polymerase chain reaction evaluation. Corneal Pentacam (Oculus, Dutenhofen, Germany) imaging was performed at least two weeks after recovery from systemic COVID-19. Measurements were repeated one and three months later.

Results. A total of 20 patients, 11 (55%) of whom were females, with a mean age of 35.5 ± 7.1 years (age range: 25–51 years) recovered from nonhospitalized COVID-19 infection, were enrolled in this study. An increase in the keratometry mean front, keratometry mean back, cornea volume, and anterior chamber depth was observed in the longitudinal evaluation; however, they showed no statistical significance. Anterior chamber volume was statistically increased at three-month follow-up, compared to baseline (baseline: 177.8 ± 36.68 mm³; three months: 182.25 ± 39.58 mm³, \( P < 0.048 \)).

Conclusion. COVID-19 infection may affect the cornea and anterior segment.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of unusual pneumonia with multiorgan damage worldwide [1]. Coronavirus disease 2019 (COVID-19) has various ophthalmic manifestations. Ocular surface, as well as corneal signs and symptoms, was reported, and the most prevalent manifestations were conjunctivitis and dry eye [2, 3]. Posterior segment involvements were numerous as cotton wool spots, retinal hemorrhages, dilated and tortuous vessels, decreased retinal microvasculature, ischemic retinal involvements, pachychoroid spectrum presentations, chorioretinitis, and optic nerve head involvement [4–7]. Furthermore, neuroinvasive actions of the virus were reported in previous studies [8, 9].

The presence of SARS-CoV-2 RNA and proteins was reported in the anterior chamber and corneal tissue following COVID-19 infection [10–13]. Moreover, some incompatible reports were on the presence of viruses on the ocular surface [14]. However, the long-term effects of COVID-19 infection on the anterior segment parameters and cornea are unclear. In posterior segment evaluations up to now, retinal thickness and vasculature have been affected in COVID-19 patients more than finding SARS-CoV-2 in retinal samples. A case-control study on 31 patients recovered from COVID-19 infection reported decreased vessel density in the superficial and deep retinal capillary plexus in the foveal and parafoveal regions [15]. In another study, remarkable changes of the macular region choroid were reported in a cross-sectional study on 34 patients recovered...
from COVID-19 infection [16]. Accordingly, this study aimed to evaluate the Pentacam parameters of the anterior segment and cornea to investigate the hypotheses of anterior segment changes secondary to uvea changes in COVID-19 infection.

2. Methods

2.1. Study Population. In this longitudinal study conducted in Khatam Eye Hospital, the participants were the hospital personnel who recovered from COVID-19 infection and came back to work. They were aged from 25 to 55 years, and the COVID-19 infection of all subjects was confirmed with nasopharyngeal swabs under reverse transcription-polymerase chain reaction test for SARS-CoV-2. The exclusion criteria were the presence of any ocular pathologic condition impairing visual function, any previous ocular surgery (except for refractive surgery more than six months ago), glaucoma or glaucoma suspect, diabetes mellitus, auto-immune diseases, pregnancy, breastfeeding, myopia more than −6.00 D or hyperopia more than +4.00 D, low-quality images, and best-corrected visual acuity less than 20/20. All subjects underwent a standard ophthalmic examination. At the time of becoming asymptomatic, at least two weeks after the diagnosis of the COVID-19 infection, the participants were asked for a baseline visit. Subsequently, examination and imaging were repeated after one and three months.

2.2. Imaging Procedures. Imaging was performed by a rotating Scheimpflug camera (Pentacam, OCULUS Optikgeräte, Germany). Keratometry mean front ($K_{m}$ front), keratometry mean back ($K_{m}$ back), cornea thinnest thickness (CCT), keratometry maximum front ($K_{max}$ front), cornea volume (CV), anterior chamber volume (ACV), and anterior chamber depth (ACD) were extracted by the analyzer software.

2.3. Statistical Analysis. Statistical analysis was performed in SPSS software (version 16; SPSS Institute, Inc., Chicago, IL, USA) through ANOVA to compare the mean values between visits.

2.4. Ethical Considerations. Regarding the declaration of Helsinki, the imaging procedures were clarified for the participants, and written informed consent was obtained from each patient. The study protocol was approved by the Ethics Committee of the Human Research at Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUMS.MEDICAL.REC.1399.597).

3. Results

A total of 20 healthy patients recovered from nonhospitalized COVID-19 infection were enrolled in this study. It is worth mentioning that the majority ($n = 11; 55\%$) of the cases were female, and the mean age of the participants was $35.5 \pm 7.12$ years (age range: 25–51 years). The mean values of the $K_{m}$ front were $42.4 \pm 2$ D, $42.45 \pm 1.94$ D, and $42.6 \pm 2.07$ D at baseline, as well as one and three months later, respectively. This increase was not statistically significant ($P = 0.19$), and there was no significant difference between the two visits (Table 1). The mean CCT values were $524.2 \pm 40.05$, $523.8 \pm 39.74$, and $526 \pm 39.58 \mu m$ at baseline, as well as one and three months later, respectively. It should be noted that there were no significant changes during the time ($P = 0.257$) and between the visits (Table 1).

Furthermore, the mean CV values were $59.68 \pm 4.22$, $59.78 \pm 4.24$, and $59.83 \pm 4.21$ at baseline, as well as one and three months later, respectively. This increase was not statistically significant ($P = 0.542$), and there were no significant changes between the two visits (Table 1). The mean ACV values were $177.8 \pm 36.68$, $180.8 \pm 44.91$, and $182.25 \pm 39.58 \text{ mm}^3$ at baseline, as well as one and three months later, with no significant increase ($P = 0.13$). However, there was a significant increase three months later, compared to the baseline ($P = 0.048$) (Table 1). Other parameter changes are depicted in Table 1.

4. Discussion

This study evaluated seven anterior chamber and cornea Pentacam parameters. The mean $K_{m}$ front, $K_{m}$ back, CV, ACD, and ACV values showed an increase during three months; however, these increases were not statistically significant. The mean CTT and $K_{max}$ front showed no significant changes in the period of the study. The comparison of these parameter values between different visits showed no significance, except for ACV. SARS-CoV-2 virus presence has been reported in the anterior chamber and cornea tissue [10–13]. Yan et al. reported the presence of nucleocapsid protein antigens on the cells of the conjunctiva, iris, and trabecular meshwork of a patient with a COVID-19 infection, and these antigens were absent on the specimens from the control patient [10]. Casagrande et al. in a case series of 11 patients with COVID-19 viremia reported the presence of viral genomic (55%) and subgenomic (67%) RNA of SARS-CoV-2 in the cornea [11]. Similarly, Sawant et al. reported that the positivity rate of SARS-CoV-2 RNA was about 13% in 132 ocular tissues from 33 surgical intended donors [12]. Koo et al. in a prospective cross-sectional study on 31 aqueous humor samples found that the SARS-CoV-2 RNA was in 19.4% of the samples [13]. However, Bayyoud et al. reported that no SARS-CoV-2 RNA was detected in the conjunctiva, anterior chamber fluid, and corneal tissues of 10 eyes of five COVID-19 patients [17]. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) for entry into target cells, and endothelial cells express abundant ACE2; moreover, the expression of ACE2 has been detected in the human aqueous humor [18, 19]. The direct and indirect effects of SARS-CoV-2 on the anterior chamber and cornea in the long term are unknown. Due to the possibility of SARS-CoV-2 presence in the anterior chamber and cornea, as well as the expression of ACE2 in the aqueous humor, it was decided to evaluate the anterior chamber and cornea Pentacam parameter changes in
participants recovered from COVID-19 infection in a longitudinal study.

In total, 40 eyes of 20 patients with no ocular pathology were investigated after recovery from COVID-19 infection with Pentacam imaging. All patients were asymptomatic and had no ocular signs or symptoms. The mean $K_m$ front, $K_m$ back, CV, ACD, and ACV showed an increase; however, they were not statistically significant. On the other hand, these changes may get significant in a more extended time and need more extended studies on a larger number of participants. In the same line, there were no significant changes in the mean CTT and $K_{\text{max}}$. The only statistically significant change in this study was the increase of ACV after three months, compared to baseline ($P = 0.048$). An increase was noticed in the ACD, which could be significant in the long term, and it could be secondary to anterior segment vascular changes.

In conclusion, the effect of COVID-19 infection on the anterior chamber and cornea was investigated in this study. The increase in some anterior chamber and cornea Pentacam parameters was not significant, except for the ACV; however, the reversibility of this effect and evaluation of other parameters need further studies on larger populations and follow-up of these patients. Our participants were from a small group of otherwise healthy nonhospitalized patients with no complications following COVID-19 infection. This point was one of our study limitations. The subjects were followed up just for three months, and more follow-ups could specify whether these changes are temporary/permanent and progressive. It was the first time that anterior segment changes in COVID-19 patients were evaluated with anterior segment modalities. Further studies to obtain accumulative evidence on COVID-19 effects on anterior segment parameters may lead to clinical application in elective intraocular surgeries, such as considering parameters in intraocular lens (IOL) calculation for phakic IOL or phacoemulsification candidates with a history of COVID-19 infection.

Further studies are recommended to evaluate iris vascularity in COVID-19 patients with anterior segment optical coherence tomography angiography and use more accurate imaging modalities than Pentacam, such as anterior segment optical coherence tomography, to evaluate anterior segment parameters.

Data Availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This study was approved by the Committee of Ethics in Human Research at Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1399.597).

Consent

Consent for publication was acquired from the patients.

Disclosure

The funding organization had no role in the design or conduct of this research.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All the authors contributed significantly to this report, and all authors agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to acknowledge the financial support of the Vice-Chancellor of Research of Mashhad University of Medical Sciences for this research project (code: 990069).

References

[1] B. Hu, H. Guo, P. Zhou, and Z.-L. Shi, “Characteristics of SARS-CoV-2 and COVID-19,” Nature Reviews Microbiology, vol. 19, no. 3, pp. 141–154, 2021.
[2] M. Abrishami, F. Tohidinezhad, R. Daneshvar et al., “Ocular manifestations of hospitalized patients with COVID-19 in northeast of Iran,” Ocular Immunology and Inflammation, vol. 28, no. 5, pp. 739–744, 2020.
[3] N. Nasiri, H. Sharifi, A. Bazrafshan, A. Noori, M. Karamouzian, and A. Sharifi, “Ocular manifestations of...
COVID-19: a systematic review and meta-analysis,” *Journal of Ophthalmic and Vision Research*, vol. 16, no. 1, pp. 103–112, 2021.

[4] G. De Salvo, A. Meduri, S. Vaz-Pereira, and D. Spencer, “An uncommon cold of the retina,” *Survey of Ophthalmology*, vol. 6257, no. 21, pp. 00178–00188, 2021.

[5] A. Invernizzi, A. Torre, S. Parrulli et al., “Retinal findings in patients with COVID-19: results from the SERPICO-19 study,” *EclinicalMedicine*, vol. 27, Article ID 100550, 2020.

[6] M. P. Pirraglia, G. Ceccarelli, A. Cerini et al., “Retinal involvement and ocular findings in COVID-19 pneumonia patients,” *Scientific Reports*, vol. 10, no. 1, p. 17419, 2020.

[7] M. Abrishami, R. Daneshvar, N. Shoeibi, N. Saeedian, H. R. Heidarzadeh, and S. M. Hosseini, “Pachychoroid spectrum disorder findings in patients with coronavirus disease 2019,” *Case Reports in Ophthalmological Medicine*, vol. 2021, Article ID 4688764, 9 pages, 2021.

[8] F. Freni, A. Meduri, F. Gazia et al., “Symptomatology in head and neck district in coronavirus disease (COVID-19): a possible neuroinvasive action of SARS-CoV-2,” *American Journal of Otolaryngology*, vol. 41, no. 5, Article ID 102612, 2020.

[9] A. Ortiz-Seller, L. Martínez Costa, A. Hernández-Pons, E. Valls Pascual, A. Solves Alemany, and M. Albert-Fort, “Ophthalmic and neuro-ophtalmic manifestations of coronavirus disease 2019 (COVID-19),” *Ocular Immunology and Inflammation*, vol. 28, no. 8, pp. 1285–1289, 2020.

[10] Y. Yan, B. Diao, Y. Liu, W. Zhang, G. Wang, and X. Chen, “Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein in the ocular tissues of a patient previously infected with coronavirus disease 2019,” *JAMA Ophthalmology*, vol. 138, no. 11, pp. 1201–1204, 2020.

[11] M. Casagrande, A. Fitzek, M. S. Spitzer et al., “Presence of SARS-CoV-2 RNA in the cornea of viremic patients with COVID-19,” *JAMA Ophthalmology*, vol. 139, no. 4, pp. 383–388, 2021.

[12] O. B. Sawant, S. Singh, R. E. Wright et al., “Prevalence of SARS-CoV-2 in human post-mortem ocular tissues,” *Ocular Surface*, vol. 19, pp. 322–329, 2021.

[13] E. H. Koo, A. O. Eghrari, D. Dzhaber et al., “Presence of SARS-CoV-2 viral RNA in aqueous humor of asymptomatic individuals,” *American Journal of Ophthalmology*, vol. 230, no. 21, pp. 151–155, 2021.

[14] A. Meduri, G. W. Oliverio, G. Mancuso et al., “Ocular surface manifestation of COVID-19 and tear film analysis,” *Scientific Reports*, vol. 10, no. 1, Article ID 20178, 2020.

[15] M. Abrishami, Z. Emamverdian, N. Shoeibi et al., “Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study,” *Canadian Journal of Ophthalmology*, vol. 56, no. 1, pp. 24–30, 2021.

[16] M. Abrishami, Z. Emamverdian, R. Daneshvar et al., “Choroidal thickening in patients with coronavirus disease-2019,” *Research Square*, 2020.

[17] T. Bayyoud, A. Iftner, T. Iftner et al., “Absence of severe acute respiratory syndrome-coronavirus-2 RNA in human corneal tissues,” *Cornea*, vol. 40, no. 3, pp. 342–347, 2021.

[18] H. K. Siddiqi, P. Libby, and P. M. Ridker, “COVID-19-a vascular disease,” *Trends in Cardiovascular Medicine*, vol. 31, no. 1, pp. 1–5, 2021.

[19] M. Gheblawi, K. Wang, and Viveiros, “Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system,” *Circulation Research*, vol. 126, pp. 1457–1475, 2020.